ARDX Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -0.82% compared to Ardelyx's net margin of -49.65%. Ardelyx's return on equity of -44.58% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Ardelyx has a consensus price target of $10.78, signalling upside risk potential of 123.84%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Ardelyx, analysts believe NovaBay Pharmaceuticals is more attractive than Ardelyx.

Ardelyx has a beta of 0.829, which suggesting that the stock is 17.08% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $98.2M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Ardelyx's net income of -$809K is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Ardelyx's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 4.47x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -0.82% compared to Ardelyx's net margin of -2357.27%. Ardelyx's return on equity of -44.58% beat Palatin Technologies's return on equity of --.

Ardelyx has a consensus price target of $10.78, signalling upside risk potential of 123.84%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Ardelyx, analysts believe Palatin Technologies is more attractive than Ardelyx.

Ardelyx has a beta of 0.829, which suggesting that the stock is 17.08% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $98.2M, which are larger than Palatin Technologies quarterly revenues of $350K. Ardelyx's net income of -$809K is higher than Palatin Technologies's net income of -$7.8M. Notably, Ardelyx's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 4.47x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics has a net margin of -0.82% compared to Ardelyx's net margin of 41.27%. Ardelyx's return on equity of -44.58% beat United Therapeutics's return on equity of 19.26%.

Ardelyx has a consensus price target of $10.78, signalling upside risk potential of 123.84%. On the other hand United Therapeutics has an analysts' consensus of $335.33 which suggests that it could grow by 9.5%. Given that Ardelyx has higher upside potential than United Therapeutics, analysts believe Ardelyx is more attractive than United Therapeutics.

Ardelyx has a beta of 0.829, which suggesting that the stock is 17.08% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.544, suggesting its less volatile than the S&P 500 by 45.563%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $98.2M, which are smaller than United Therapeutics quarterly revenues of $748.9M. Ardelyx's net income of -$809K is lower than United Therapeutics's net income of $309.1M. Notably, Ardelyx's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 15.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 4.47x versus 6.38x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of -0.82% compared to Ardelyx's net margin of 28.56%. Ardelyx's return on equity of -44.58% beat Zoetis's return on equity of 48%.

Ardelyx has a consensus price target of $10.78, signalling upside risk potential of 123.84%. On the other hand Zoetis has an analysts' consensus of $214.22 which suggests that it could grow by 29.96%. Given that Ardelyx has higher upside potential than Zoetis, analysts believe Ardelyx is more attractive than Zoetis.

Ardelyx has a beta of 0.829, which suggesting that the stock is 17.08% less volatile than S&P 500. In comparison Zoetis has a beta of 0.889, suggesting its less volatile than the S&P 500 by 11.103%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.05% to investors and pays a quarterly dividend of $0.43 per share. Ardelyx pays -- of its earnings as a dividend. Zoetis pays out 29.52% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ardelyx quarterly revenues are $98.2M, which are smaller than Zoetis quarterly revenues of $2.4B. Ardelyx's net income of -$809K is lower than Zoetis's net income of $682M. Notably, Ardelyx's price-to-earnings ratio is -- while Zoetis's PE ratio is 30.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 4.47x versus 8.23x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.